XTX Topco Ltd Has $241,000 Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

XTX Topco Ltd reduced its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 79.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,670 shares of the biotechnology company’s stock after selling 125,276 shares during the quarter. XTX Topco Ltd’s holdings in BioCryst Pharmaceuticals were worth $241,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. CWM LLC boosted its stake in BioCryst Pharmaceuticals by 200.0% during the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after buying an additional 3,772 shares in the last quarter. Signaturefd LLC boosted its position in shares of BioCryst Pharmaceuticals by 560.5% during the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 5,599 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 1,322 shares during the period. nVerses Capital LLC acquired a new position in BioCryst Pharmaceuticals in the second quarter worth about $63,000. Finally, DRW Securities LLC acquired a new position in BioCryst Pharmaceuticals in the second quarter worth about $74,000. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX opened at $7.31 on Thursday. The company has a market capitalization of $1.51 billion, a P/E ratio of -11.98 and a beta of 1.79. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $8.88. The business’s 50 day simple moving average is $7.62 and its 200-day simple moving average is $7.42.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. BioCryst Pharmaceuticals’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.19) EPS. On average, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Barclays increased their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.60.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.